• Sample Available

• MOQ Flexible

• Fast Quotation Within 24 Hours

Please contact us for COA, HPLC reports, pricing, and bulk order information.

Tirzepatide has been shown to help lose weight in overweight patients. Phase 3 clinical trials are currently underway for weight loss in adults who are overweight, obese, or have weight-related health issues. Tirzepatide has received FDA Fast Track designation to speed up its FDA application for treating adults with obesity, or who are overweight with weight-related health conditions.
In the SURMOUNT-1 clinical trial, the average weight loss with tirzepatide after 72 weeks was 15% for the 5mg dose, 19.5% for the 10mg dose, and 20.9% for the 15mg dose.

tirzepatide is a once-weekly glucose-dependent-stimulating polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by scientists. ChemicalbookGIP and GLP-1 are both hormones secreted by the gut that promote secretion. tirzepatide combines the effects of two -promoting drugs into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

How much weight can you lose in a week with tirzepatide?
Clinical trials have shown that study participants taking a weekly dose of semaglutide had an average reduction in body weight of 5-10 percent.

Description:

Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes. Tirzepatide (LY3298176) shows significantly better efficacy with regard to glucose control and weight loss than do Dulaglutide.

Tirzepatide, also known as LY 3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. Tirzepatide was approved for improving blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.

Product Features

✅ High purity research compound
✅ HPLC analytical testing available
✅ LC-MS identification support
✅ Stable powder formulation
✅ Batch-to-batch consistency
✅ Custom packaging available
✅ Bulk supply capability

Quality Control

Available documents:

✔ COA (Certificate of Analysis)
✔ HPLC Purity Report
✔ LC-MS Report
✔ Batch Testing Data
✔ Product Specification Sheet

Packaging Options

Common Packaging:

• 5mg / vial
• 10mg / vial
• 25mg / vial
• 50mg / vial
• 100mg / vial

Custom packaging available.

Storage & Shipping

Storage:

• Store at -20°C
• Keep dry and protected from light
• Avoid repeated freeze-thaw cycles

Shipping:

✈ International Express
✈ Air Freight
✈ Customized Export Solutions

MOQ & Supply

MOQ: Negotiable
Purity: ≥98% HPLC
Sample Order: Available
Bulk Supply: Supported

Why Choose Us

✔ Professional research compound manufacturer
✔ Strict QC system
✔ Competitive factory pricing
✔ Reliable export service
✔ Fast communication and support